10-Year Study: Stendra’s Cardiovascular Safety in American Men with ED
Reading Time: 2 minutes Introduction Stendra (avanafil), a phosphodiesterase type 5 (PDE5) inhibitor, has been widely used for the treatment of erectile dysfunction (ED) since its approval by the FDA. While its efficacy in managing ED is well-documented, the long-term effects of Stendra on cardiovascular health remain a topic of significant interest and concern. This article delves into a comprehensive 10-year prospective study conducted on American men to evaluate the cardiovascular implications of prolonged Stendra use. Study Design and Methodology The study involved 500 American men aged 40-70 years diagnosed with ED and prescribed Stendra. Participants were followed annually for a decade, with detailed...


